Biotech: Page 87
-
Grail, Illumina's well-funded liquid biopsy spinout, prepares for IPO
The company claims its test may help avert deaths from cancers that would otherwise kill later on, but will have a tough task convincing doctors and payers of its merit.
By Nick Paul Taylor • Sept. 9, 2020 -
Danielle Ternes/BioPharma Dive
Deep DiveHow biotech and pharma companies pay their CEOs, and their workers
The median CEO of 231 drug companies analyzed by BioPharma Dive earned 50% more last year than in 2017, a leap that far outpaced the more modest pay gains among employees.
By Ned Pagliarulo • Sept. 9, 2020 -
Cancer drug approval puts Blueprint up against Lilly
Gavreto is cleared to treat certain lung cancer patients who have so-called RET mutations. Partners Blueprint and Roche will now compete with Eli Lilly and its rival drug Retevmo.
By Jacob Bell , Ben Fidler • Sept. 8, 2020 -
AbbVie wagers up to $2B on a Chinese biotech's cancer drug
The licensing deal hands AbbVie exclusive rights to a drug targeting CD47, a protein that has caught the attention of drugmakers like Gilead and Celgene.
By Jacob Bell • Sept. 4, 2020 -
Amarin loses appeal of court ruling on heart drug patents
The federal appeals court decision makes the launch of generic competitors to Amarin's Vascepa more likely, dealing the drugmaker a major blow.
By Ned Pagliarulo • Sept. 3, 2020 -
Akebia stumbles and clouds the prospects of anemia pills
The biotech's drug was found to be less safe than an injectable anemia medicine in a Phase 3 trial, dimming its potential approval chances.
By Ben Fidler • Sept. 3, 2020 -
After a rare win, a biotech details long-awaited results for its ALS drug
Newly published data describe what one study investigator deems a milestone in the fight against ALS, a deadly and progressive neurological disorder.
By Jacob Bell • Sept. 2, 2020 -
Intercept, facing long road ahead for NASH drug, lays off quarter of workforce
In late June, the FDA rejected Intercept's obeticholic acid for the liver disease, asking for more data that could take the biotech some time to collect.
By Ned Pagliarulo • Sept. 2, 2020 -
Permission granted by Gilead Sciences
Gilead deal reignites optimism in a cancer biotech
A year after Jounce Therapeutics and Celgene ended a wide-ranging alliance, Gilead has teamed up with the Massachusetts biotech.
By Jacob Bell • Sept. 1, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158908/in/album-72157713108522106/.
Vir, GSK push coronavirus antibody drug straight into mid-stage tests
The two companies, chasing rival treatments from Eli Lilly, Regeneron and more, aim to produce their first study results by the end of the year.
By Jonathan Gardner • Aug. 31, 2020 -
Ionis, changing its strategy, reels its spinoff back in
Reversing course on plans to rely on others to sell its drugs, the biotech will spend about half a billion dollars to acquire its own spinoff, Akcea.
By Jacob Bell • Aug. 31, 2020 -
Sponsored by Parexel Biotech
Top 10 myths about working with the FDA for an oncology drug approval
Debunking myths around working with the FDA for oncology drug approval.
By Amy McKee, Vice President Regulatory Consulting Services, Parexel • Aug. 31, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
CanSino said to seek early authorization of coronavirus vaccine
The reported talks between CanSino and several countries highlight the urgency with which governments are operating to secure supply of experimental coronavirus vaccines.
By Jonathan Gardner • Aug. 28, 2020 -
Permission granted by BioNTech SE
Moderna's vaccine may have an edge when immunization programs roll out
A rival shot from Pfizer and BioNTech needs to be stored at colder temperatures and doesn't last as long in a refrigerator, which may limit its use.
By Jonathan Gardner • Aug. 26, 2020 -
A new biotech forms to revive Amgen's old heart drug
Founders of Dutch biotech Dezima have created NewAmsterdam Pharma and bought back the cholesterol drug they sold to Amgen in 2015.
By Ben Fidler • Aug. 26, 2020 -
Moderna says its coronavirus vaccine sparks immune response in older people
An initial look at the vaccine's effects on the elderly shows those in their 70s had similar responses to those under 55, Moderna told a government panel.
By Jonathan Gardner • Aug. 26, 2020 -
Freenome raises $270M to run pivotal trial of colorectal cancer blood test
The 14,000-person study could set the company up to compete with Exact Sciences and Guardant Health for the colorectal cancer screening market.
By Nick Paul Taylor • Aug. 26, 2020 -
Sarepta, after two dramatic approvals, gets an FDA review for next Duchenne drug
Sarepta's first two medicines were both cleared in controversial fashion. Will its third attempt go more smoothly?
By Jonathan Gardner • Aug. 25, 2020 -
New data lead Ovid, Takeda to push seizure drug into final testing
The partner companies found that, when tested in two types of rare epilepsy, their drug seems to perform better in one. But they see a path forward in both.
By Jacob Bell • Aug. 25, 2020 -
Moderna joins other vaccine leaders in European supply talks
The deal would designate up to 160 million doses of Moderna's shot for the European Union, which has worked aggressively of late to bolster its supply.
By Jonathan Gardner • Aug. 24, 2020 -
Proteostasis bows out of cystic fibrosis drugmaking through Yumanity merger
The biotech's plans to challenge Vertex Pharmaceuticals have fallen short, leading to a merger with a neuroscience-focused startup.
By Jacob Bell • Aug. 24, 2020 -
Permission granted by Relay Therapeutics
Deep DiveRelay Therapeutics set out to change how drugs are designed. Can it continue what Vertex began?
Vertex pioneered a more precise way of developing drugs. Relay, which has raised nearly $1 billion since its founding, thinks it can go one step further.
By Ned Pagliarulo • Aug. 24, 2020 -
Permission granted by BioNTech SE
Coronavirus vaccine Pfizer, BioNTech chose for late-stage testing appears safer than first
Preliminary data showed the pair's second experimental shot caused less fever, without compromising potency, when compared to an earlier version.
By Jonathan Gardner • Updated Aug. 21, 2020 -
Getty / Edited by BioPharma Dive
BioMarin's gene therapy rejection didn't shock everyone
The FDA's decision not to approve Roctavian raises the question of why BioMarin was able to submit the hemophilia A therapy in the first place.
By Jacob Bell • Aug. 20, 2020 -
Mylan launches copy of Biogen's top drug despite ongoing court battle
Mylan's launch of a generic copy of the multiple sclerosis drug Tecfidera comes earlier than expected, and risks a court siding with Biogen on a key patent.
By Ben Fidler • Aug. 19, 2020
Previous
